

Supplementary Information

Reversal of Remimazolam-Mediated Inhibition of Jurkat T Cell Activation by TGFBI Depletion

Hao Wang [†], Ge Gao [†], Haoyuan Ma, Yingcheng Qi, Bowen Zhang, Tingting Liu, Yang Liu, Tianhan Li, Lichen Zhang, Hui Wang, Yinming Liang ^{*} and Binhui Zhou ^{*}




Figure S1. Gate strategies for the analysis of CD69 expression and p-ERK levels in WT or TGFBI^{-/-} Jurkat T cells following various treatments. (A) Gate strategies for the analysis of CD69 expression on Jurkat T cells following various treatments. (B) Gate strategies for the analysis of CD69 expression on WT and TGFBI^{-/-} Jurkat T cells in a steady state. (C) Gate strategies for the analysis of CD69 expression on WT and TGFBI^{-/-} Jurkat T cells following P+I treatment. (D) Gate strategies for the analysis of CD69 expression on WT and TGFBI^{-/-} Jurkat T cells following P+I+Remi treatment. (E, F) Gate strategies for the analysis of p-ERK levels in WT and TGFBI^{-/-} Jurkat T cells following DMSO (NT) or P+I treatments. (G) Gate strategies for the analysis of CD69 expression on TGFBI^{-/-} Jurkat T cells following P+I or P+I+Remi treatment.




Figure S2. Knockout of TGFBI reduces GABA production by Jurkat T cells. **(A)** Mass spectrometry detection of GABA in WT and TGFBI knockout Jurkat T cells (up) and their corresponding culture medium following stimulation with or without P+I. **(B)** Quantification of GABA levels in WT and TGFBI deficiency Jurkat T cells and culture medium following stimulation with or without P+I. Statistical significance is denoted as follows: ** $p < 0.01$, **** $p < 0.0001$, unpaired Student's t -test.